Neoadjuvant targeted therapy for lung cancer patients with specific mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the safety and feasibility of using osimertinib, a targeted therapy, as a neoadjuvant treatment for patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma. The study aims to determine if this approach can effectively reduce tumor size and improve surgical outcomes. Previous trials have shown benefits of neoadjuvant therapy in other types of lung cancer, but this specific population has been underrepresented in clinical research. The trial will enroll patients who meet specific eligibility criteria, including confirmed EGFR mutations and no metastasis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Chest CT and pathological examination confirmed as resectable II-IIIB lung squamous cell carcinoma;
2. Gene text confirmed EGFR mutation;
3. PET-CT confirmed no metastasis;
4. ECOG physical status score 0-1;
5. Age ≥ 18 years;
6. Have one measurable lesion at least;
7. Good function of other major organs (liver, kidney, blood system, etc.):-absolute neutrophil count ((ANC) ≥ 1.5 × 109), platelet (≥ 100 × 109), hemoglobin (≥ 90g/L). Note: patients shall not receive blood transfusion or growth factor support within 14 days before blood collection during the screening period;-International standardized ratio (INR) or prothrombin time (PT) ≤ 1.5 × normal upper limit (ULN);-activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;- serum total bilirubin ≤ 1.5 × ULN (Gilbert syndrome patients with total bilirubin must be \< 3×ULN). Fertile female patients with aspartate and alanine aminotransferase (AST and ALT) ≤ 2.5 × ULN, or liver metastasis with AST and ALT ≤ 5 × ULN
8. Fertile female patients must voluntarily take effective contraceptive measures more than 120 days after treatment, and the urine or serum pregnancy test results less than 7 days before entering the group were negative. Unsterilized male patients must voluntarily take effective contraceptive measures ≥ 120 days after treatment;
9. Sign informed consent.

Exclusion Criteria:

1. Patients with other malignant tumors in the five years before the start of this trial.
2. Complicated with unstable systemic diseases, including active infections, uncontrolled hypertension, unstable angina pectoris, congestive heart failure \[higher than II (New York College of Cardiology)\], severe arrhythmias, liver, kidney or metabolic diseases;
3. Active, known or suspected autoimmune diseases, or autoimmune paraneoplastic syndrome requiring systemic treatment;
4. A history of active bleeding or embolism within 6 months, or received thrombolysis or anticoagulation therapy, or the researchers believe that there is an obvious tendency of gastrointestinal bleeding (such as esophageal varices have the risk of bleeding, local active ulcer lesions, etc.);
5. Allergic to experimental drugs;
6. Complicated with HIV infection or active hepatitis.
7. Vaccination within 4 weeks before the start of this trial;
8. Those who had undergone other major operations or severe injuries within the previous 2 months;
9. Clinically uncontrolled pleural effusion or ascites requiring pleural or abdominal puncture drainage within 2 weeks before admission;
10. Pregnant or lactating women;
11. Those with neurological diseases or mental disorders;
12. Participated in another therapeutic clinical study at the same time;
13. Other researchers did not consider it appropriate to enroll in the group.

Where it's running

• The First Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Shuben Li, Doctor
• Email: 13500030280@163.com
• Phone: 13500030280

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Osimertinib before radiation and as maintenance for chemo-ineligible Stage III EGFR‑mutant unresectable NSCLC

  This phase 2 trial will test whether giving osimertinib before definitive radiation and continuing it afterward helps adults with Stage III unresectable EGFR‑mutant NSCLC who can't or won't have chemotherapy.

  Recruiting at 18 sites Phase 2 AstraZeneca · Beijing and 19 other locations · NCT07295821

• Combining osimertinib and carotuximab for advanced lung cancer treatment

  This study is testing a new combination of two drugs, osimertinib and carotuximab, to see if it can safely help people with advanced lung cancer caused by specific genetic changes.

  Recruiting at 5 sites Phase 1 Cedars-Sinai Medical Center · Beverly Hills, California and 4 other locations · NCT05401110

• Osimertinib to slow growth of remaining ground-glass nodules after lung cancer surgery

  This will try daily oral osimertinib (80 mg) to slow or stop growth of persistent ground-glass nodules in adults who had surgery for stage I lung adenocarcinoma with an L858R or exon 19 EGFR mutation.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Kangnamgu and 1 other locations · NCT04591002

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Osimertinib with Cyclosporine A for EGFR-mutant NSCLC

  This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07874490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.